FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3012937015> ?p ?o ?g. }

• W3012937015 endingPage "2592" @default.
• W3012937015 startingPage "2583" @default.
• W3012937015 abstract "Abstract Objective The goal of this study was to evaluate the long-term impact of adalimumab therapy on work-related outcomes in employed patients with rheumatoid arthritis (RA). Method We utilized data from an observational cohort of German patients who initiated adalimumab treatment during routine clinical care. Analyses were based on employed patients (part-time or full-time) who continued adalimumab treatment for 24 months. Major outcomes were self-reported sick leave days in the previous 6 months, absenteeism, presenteeism, and total work productivity impairment as assessed by the Work Productivity and Activity Impairment (WPAI) questionnaire and disease activity assessments. The normal number of sick leave days was based on data from the German Federal Statistical Office. Results Of 783 patients, 72.3% were women, mean age was 47.9 years, and mean disease duration was 7.8 years. At baseline (before adalimumab initiation), 42.9% of patients had higher than normal sick leave days (> 5) in the previous 6 months. During 24 months of adalimumab treatment, 61% of patients with higher than normal sick leave days at baseline returned to normal sick leave values (≤ 5 days/6 months). Overall, mean sick leave days/6 months decreased from 14.8 days at baseline to 7.4 days at month 24. Improvements were observed in WPAI assessments and disease activity measures, although presenteeism levels remained high (32.2% at month 24). Conclusions Adalimumab treatment was associated with strong and sustained improvements in work-related outcomes in employed patients who continued on adalimumab for 24 months. Presenteeism appears to be the work outcome most resistant to improvement during RA treatment. Trial registration NCT01076205 Key Points • Long-term adalimumab therapy was associated with sustained improvements in work outcomes in patients with rheumatoid arthritis. • Despite improvements in sick leave days and work absenteeism, presenteeism (impairment while at work) remained relatively high." @default.
• W3012937015 created "2020-03-27" @default.
• W3012937015 creator A5012842018 @default.
• W3012937015 creator A5028673926 @default.
• W3012937015 creator A5032343417 @default.
• W3012937015 creator A5036606557 @default.
• W3012937015 creator A5060117684 @default.
• W3012937015 creator A5074627741 @default.
• W3012937015 creator A5077673047 @default.
• W3012937015 creator A5082216825 @default.
• W3012937015 date "2020-03-23" @default.
• W3012937015 modified "2023-09-26" @default.
• W3012937015 title "Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study" @default.
• W3012937015 cites W1121141779 @default.
• W3012937015 cites W1523138578 @default.
• W3012937015 cites W1559860156 @default.
• W3012937015 cites W1965122156 @default.
• W3012937015 cites W1971839397 @default.
• W3012937015 cites W1980705643 @default.
• W3012937015 cites W1981423029 @default.
• W3012937015 cites W2070302677 @default.
• W3012937015 cites W2086696463 @default.
• W3012937015 cites W2087668087 @default.
• W3012937015 cites W2097469703 @default.
• W3012937015 cites W2106148556 @default.
• W3012937015 cites W2110177517 @default.
• W3012937015 cites W2125748229 @default.
• W3012937015 cites W2162260707 @default.
• W3012937015 cites W2165437170 @default.
• W3012937015 cites W2255303688 @default.
• W3012937015 cites W2299605132 @default.
• W3012937015 cites W2334963307 @default.
• W3012937015 cites W2342923384 @default.
• W3012937015 cites W2403707357 @default.
• W3012937015 cites W2528269009 @default.
• W3012937015 cites W2565339015 @default.
• W3012937015 cites W2570670433 @default.
• W3012937015 cites W2585158795 @default.
• W3012937015 cites W2604481210 @default.
• W3012937015 cites W2605904613 @default.
• W3012937015 cites W2759906331 @default.
• W3012937015 cites W2806116197 @default.
• W3012937015 cites W352980755 @default.
• W3012937015 cites W4211111012 @default.
• W3012937015 doi "https://doi.org/10.1007/s10067-020-05038-y" @default.
• W3012937015 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7426289" @default.
• W3012937015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32474886" @default.
• W3012937015 hasPublicationYear "2020" @default.
• W3012937015 type Work @default.
• W3012937015 sameAs 3012937015 @default.
• W3012937015 citedByCount "4" @default.
• W3012937015 countsByYear W30129370152021 @default.
• W3012937015 countsByYear W30129370152022 @default.
• W3012937015 countsByYear W30129370152023 @default.
• W3012937015 crossrefType "journal-article" @default.
• W3012937015 hasAuthorship W3012937015A5012842018 @default.
• W3012937015 hasAuthorship W3012937015A5028673926 @default.
• W3012937015 hasAuthorship W3012937015A5032343417 @default.
• W3012937015 hasAuthorship W3012937015A5036606557 @default.
• W3012937015 hasAuthorship W3012937015A5060117684 @default.
• W3012937015 hasAuthorship W3012937015A5074627741 @default.
• W3012937015 hasAuthorship W3012937015A5077673047 @default.
• W3012937015 hasAuthorship W3012937015A5082216825 @default.
• W3012937015 hasBestOaLocation W30129370151 @default.
• W3012937015 hasConcept C126322002 @default.
• W3012937015 hasConcept C162324750 @default.
• W3012937015 hasConcept C1862650 @default.
• W3012937015 hasConcept C187736073 @default.
• W3012937015 hasConcept C198451711 @default.
• W3012937015 hasConcept C201903717 @default.
• W3012937015 hasConcept C23131810 @default.
• W3012937015 hasConcept C27400517 @default.
• W3012937015 hasConcept C2776737852 @default.
• W3012937015 hasConcept C2777575956 @default.
• W3012937015 hasConcept C2779382274 @default.
• W3012937015 hasConcept C2780132546 @default.
• W3012937015 hasConcept C71924100 @default.
• W3012937015 hasConcept C72563966 @default.
• W3012937015 hasConceptScore W3012937015C126322002 @default.
• W3012937015 hasConceptScore W3012937015C162324750 @default.
• W3012937015 hasConceptScore W3012937015C1862650 @default.
• W3012937015 hasConceptScore W3012937015C187736073 @default.
• W3012937015 hasConceptScore W3012937015C198451711 @default.
• W3012937015 hasConceptScore W3012937015C201903717 @default.
• W3012937015 hasConceptScore W3012937015C23131810 @default.
• W3012937015 hasConceptScore W3012937015C27400517 @default.
• W3012937015 hasConceptScore W3012937015C2776737852 @default.
• W3012937015 hasConceptScore W3012937015C2777575956 @default.
• W3012937015 hasConceptScore W3012937015C2779382274 @default.
• W3012937015 hasConceptScore W3012937015C2780132546 @default.
• W3012937015 hasConceptScore W3012937015C71924100 @default.
• W3012937015 hasConceptScore W3012937015C72563966 @default.
• W3012937015 hasFunder F4320332418 @default.
• W3012937015 hasIssue "9" @default.
• W3012937015 hasLocation W30129370151 @default.
• W3012937015 hasLocation W30129370152 @default.
• W3012937015 hasOpenAccess W3012937015 @default.
• W3012937015 hasPrimaryLocation W30129370151 @default.

• next